118 related articles for article (PubMed ID: 36637424)
1. SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors.
Huang Z; Li X; Tang B; Li H; Zhang J; Sun R; Ma J; Pan Y; Yan B; Zhou Y; Ding D; Yan Y; Jimenez R; Orme JJ; Jin X; Yang J; Huang H; Jia Z
Cancer Res; 2023 Mar; 83(6):875-889. PubMed ID: 36637424
[TBL] [Abstract][Full Text] [Related]
2. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
[TBL] [Abstract][Full Text] [Related]
3. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.
Pan W; Cox S; Hoess RH; Grafström RH
Cancer Res; 2001 Apr; 61(7):2885-91. PubMed ID: 11306463
[TBL] [Abstract][Full Text] [Related]
4. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer.
Zhou Y; Jin X; Ma J; Ding D; Huang Z; Sheng H; Yan Y; Pan Y; Wei T; Wang L; Wu H; Huang H
Cancer Res; 2021 Mar; 81(6):1486-1499. PubMed ID: 33419772
[TBL] [Abstract][Full Text] [Related]
5. B cell antigen receptor-mediated activation of cyclin-dependent retinoblastoma protein kinases and inhibition by co-cross-linking with Fc gamma receptors.
Tanguay D; Pavlovic S; Piatelli MJ; Bartek J; Chiles TC
J Immunol; 1999 Sep; 163(6):3160-8. PubMed ID: 10477583
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
7. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability.
Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y
Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Gelbert LM; Cai S; Lin X; Sanchez-Martinez C; Del Prado M; Lallena MJ; Torres R; Ajamie RT; Wishart GN; Flack RS; Neubauer BL; Young J; Chan EM; Iversen P; Cronier D; Kreklau E; de Dios A
Invest New Drugs; 2014 Oct; 32(5):825-37. PubMed ID: 24919854
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression.
Jin X; Ding D; Yan Y; Li H; Wang B; Ma L; Ye Z; Ma T; Wu Q; Rodrigues DN; Kohli M; Jimenez R; Wang L; Goodrich DW; de Bono J; Dong H; Wu H; Zhu R; Huang H
Mol Cell; 2019 Jan; 73(1):22-35.e6. PubMed ID: 30527665
[TBL] [Abstract][Full Text] [Related]
10. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ
Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246
[TBL] [Abstract][Full Text] [Related]
11. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.
McClendon AK; Dean JL; Rivadeneira DB; Yu JE; Reed CA; Gao E; Farber JL; Force T; Koch WJ; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2747-55. PubMed ID: 22751436
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
Wang J; Walsh K
Cell Growth Differ; 1996 Nov; 7(11):1471-8. PubMed ID: 8930396
[TBL] [Abstract][Full Text] [Related]
13. Docking-dependent regulation of the Rb tumor suppressor protein by Cdk4.
Wallace M; Ball KL
Mol Cell Biol; 2004 Jun; 24(12):5606-19. PubMed ID: 15169919
[TBL] [Abstract][Full Text] [Related]
14. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
17. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
Elangovan S; Hsieh TC; Wu JM
Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
[TBL] [Abstract][Full Text] [Related]
18. A Cdk4/6-dependent phosphorylation gradient regulates the early to late G1 phase transition.
Kaulich M; Link VM; Lapek JD; Lee YJ; Glass CK; Gonzalez DJ; Dowdy SF
Sci Rep; 2021 Jul; 11(1):14736. PubMed ID: 34282211
[TBL] [Abstract][Full Text] [Related]
19. Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb.
Li J; Tsai MD
Biochemistry; 2002 Mar; 41(12):3977-83. PubMed ID: 11900540
[TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
